Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Capital Expenditures: 2020-2024

Historic Capital Expenditures for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to $563,000.

  • ARS Pharmaceuticals' Capital Expenditures fell 4043.57% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $641,000, marking a year-over-year increase of 277.06%. This contributed to the annual value of $563,000 for FY2024, which is 221.71% up from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Capital Expenditures of $563,000 as of FY2024, which was up 221.71% from $175,000 recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Capital Expenditures peaked at $917,000 during FY2020, and registered a low of $55,000 during FY2021.
  • Over the past 3 years, ARS Pharmaceuticals' median Capital Expenditures value was $199,000 (recorded in 2022), while the average stood at $312,333.
  • In the last 5 years, ARS Pharmaceuticals' Capital Expenditures slumped by 94.00% in 2021 and then surged by 261.82% in 2022.
  • Yearly analysis of 5 years shows ARS Pharmaceuticals' Capital Expenditures stood at $917,000 in 2020, then slumped by 94.00% to $55,000 in 2021, then skyrocketed by 261.82% to $199,000 in 2022, then decreased by 12.06% to $175,000 in 2023, then skyrocketed by 221.71% to $563,000 in 2024.